Lanifibranor controlled body weight gain, improved insulin sensitivity, attenuated hepatic steatosis, inflammation, ballooning, and fibrosis, as well as inhibited the expression of pro-fibrotic and inflammatory genes, and increased the expression of β-oxidation genes in studies with various preclinical models of NASH [161]. This evidence concerns the gene INS and fatty liver disease.